keyword
MENU ▼
Read by QxMD icon Read
search

Prostate pet

keyword
https://www.readbyqxmd.com/read/28417160/diagnosis-of-recurrent-prostate-cancer-with-pet-ct-imaging-using-the-gastrin-releasing-peptide-receptor-antagonist-68-ga-rm2-preliminary-results-in-patients-with-negative-or-inconclusive-18-f-fluoroethylcholine-pet-ct
#1
Gesche Wieser, Ilinca Popp, H Christian Rischke, Vanessa Drendel, Anca-Ligia Grosu, Mark Bartholomä, Wolfgang A Weber, Rosalba Mansi, Ulrich Wetterauer, Wolfgang Schultze-Seemann, Philipp T Meyer, Cordula Annette Jilg
PURPOSE/BACKGROUND: [(18)F]fluoroethylcholine ((18)FECH) has been shown to be a valuable PET-tracer in recurrent prostate cancer (PCa), but still has limited accuracy. RM2 is a gastrin-releasing peptide receptor (GRPr) antagonist that binds to GRPr on PCa cells. Recent studies suggest that GRPr imaging with PET/CT is a promising technique for staging and restaging of PCa. We explore the value of GRPr-PET using the (68)Ga-labeled GRPr antagonist RM2 in a selected population of patients with biochemically recurrent PCa and a negative/inconclusive (18)FECH-PET/CT...
April 18, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28415771/11c-choline-pet-ct-and-whole-body-mri-including-diffusion-weighted-imaging-for-patients-with-recurrent-prostate-cancer
#2
Hinrich Wieder, Ambros J Beer, Konstantin Holzapfel, Martin Henninger, Tobias Maurer, Sarah Schwarzenboeck, Ernst J Rummeny, Matthias Eiber, Jens Stollfuss
PURPOSE: To compare the detection efficacy of 11C-choline positron emission tomography and computed tomography (PET/CT) with whole-body magnetic resonance imaging (MRI) including diffusion-weighted imaging (DWI) in patients with suspected recurrent prostate cancer. MATERIAL AND METHODS: Fifty-seven patients (mean age 68, range 54-80 years) underwent 11C-choline PET/CT and MRI using T1-weighted (T1w), short-tau inversion recovery (STIR), and DWI. Two readers visually rated suspicious lesions on a 5-point scale in 20 different regions...
March 15, 2017: Oncotarget
https://www.readbyqxmd.com/read/28409220/pet-and-pet-ct-with-radiolabeled-choline-in-prostate-cancer-a-critical-reappraisal-of-20-years-of-clinical-studies
#3
REVIEW
Giampiero Giovacchini, Elisabetta Giovannini, Rossella Leoncini, Mattia Riondato, Andrea Ciarmiello
We here aim to provide a comprehensive and critical review of the literature concerning the clinical applications of positron emission tomography/computed tomography (PET/CT) with radiolabeled choline in patients with prostate cancer (PCa). We will initially briefly summarize the historical context that brought to the synthesis of [(11)C]choline, which occurred exactly 20 years ago. We have arbitrarily grouped the clinical studies in three different periods, according to the year in which they were published and according to their relation with their applications in urology, radiotherapy and oncology...
April 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28408532/-68-ga-thp-psma-a-pet-imaging-agent-for-prostate-cancer-offering-rapid-room-temperature-one-step-kit-based-radiolabeling
#4
Jennifer D Young, Vincenzo Abbate, Cinzia Imberti, Levente K Meszaros, Michelle T Ma, Samantha Y A Terry, Robert C Hider, Greg E Mullen, Philip J Blower
The clinical impact and accessibility of (68)Ga tracers for the prostate-specific membrane antigen (PSMA) and other targets would be greatly enhanced by the availability of a simple, one-step kit-based labeling process. Radiopharmacy staff are accustomed to such procedures in the daily preparation of (99m)Tc radiopharmaceuticals. Currently, chelating agents used in (68)Ga radiopharmaceuticals do not meet this ideal. AIM: To develop and evaluate preclinically a (68)Ga radiotracer for imaging PSMA expression that could be radiolabeled simply by addition of (68)Ga generator eluate to a cold kit...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28408531/-68-ga-psma-11-pet-ct-interobserver-agreement-for-prostate-cancer-assessments-an-international-multicenter-prospective-study
#5
Wolfgang Peter Fendler, Jeremie Calais, Martin Allen-Auerbach, Christina Bluemel, Nina Eberhardt, Louise Emmett, Pawan Gupta, Markus Hartenbach, Thomas A Hope, Shozo Okamoto, Christian Helmut Pfob, Thorsten D Pöppel, Christoph Rischpler, Sarah Schwarzenböck, Vanessa Stebner, Marcus Unterrainer, Helle D Zacho, Tobias Maurer, Christian Gratzke, Alexander Crispin, Johannes Czernin, Ken Herrmann, Matthias Eiber
Background: The interobserver agreement for (68)Ga-PSMA-11 Positron Emission Tomography/Computed Tomography (PET/CT) study interpretations in patients with prostate cancer is unknown. Methods:(68)Ga-PSMA-11 PET/CT was performed in 50 patients with prostate cancer for biochemical recurrence (n = 25), primary diagnosis (n = 10), biochemical persistence after primary therapy (n = 5) or staging of known metastatic disease (n = 10). Images were reviewed by 16 observers who used a standardized approach for interpretation of local (T), nodal (N), bone (Mb), or visceral (Mc) involvement...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28408526/gallium-68-or-fluorine-18-for-prostate-cancer-imaging
#6
Claudia Kesch, Clemens Kratochwil, Walter Mier, Klaus Kopka, Frederik L Giesel
The introduction of prostate specific membrane antigen (PSMA)-positron emission tomography (PET) using (68)Ga revolutionized prostate cancer imaging. Outperforming standard imaging, it allows complete staging of the local tumor and possible lymph nodes, visceral or bone metastases with high accuracy in only one examination (1,2). Sensitivities of 66% and specificities of 99% were observed for primary lymph node staging. Moreover, it has become an excellent staging tool for recurrent prostate cancer even at early stage and low PSA levels...
April 13, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28401244/integrated-68-ga-hbed-cc-psma-pet-mri-in-patients-with-suspected-recurrent-prostate-cancer
#7
Susanne Lütje, Joseph Cohnen, Benedikt Gomez, Johannes Grüneisen, Lino Sawicki, Herbert Rübben, Andreas Bockisch, Lale Umutlu, Thorsten D Pöppel, Axel Wetter
AIM: Evaluate the diagnostic accuracy of (68)Ga-labeled HBED-CC-PSMA-PET/MRI for detection of recurrent PCa in comparison to PET/CT. METHODS: 48 patients with suspected recurrent PCa underwent PET/CT after injection of the (68)Ga-HBED-CC-PSMA ligand followed by integrated PET/MRI. Image analysis was performed by nuclear medicine physicians and radiologists with respect to the detection of lymph node metastases, bone metastases and local recurrence of the tumour...
April 12, 2017: Nuklearmedizin. Nuclear Medicine
https://www.readbyqxmd.com/read/28396816/psma-pet-ct-positive-paget-disease-in-a-patient-with-newly-diagnosed-prostate-cancer-imaging-and-bone-biopsy-findings
#8
Michael Froehner, Marieta Toma, Klaus Zöphel, Vladimir Novotny, Michael Laniado, Manfred P Wirth
A 67-year-old man diagnosed with Gleason score 4 + 5 = 9 clinically localized prostate cancer with (68)Ga-labeled prostate-specific membrane antigen-targeted ligand positron emission tomography/computed tomography (PSMA-PET/CT) positive Paget bone disease is described. Immunohistochemical staining revealed weak PSMA positivity of the bone lesion supporting the hypothesis that neovasculature might explain positive PSMA-PET/CT findings in Paget disease.
2017: Case Reports in Urology
https://www.readbyqxmd.com/read/28396727/multimodality-imaging-using-proton-magnetic-resonance-spectroscopic-imaging-and-18-f-fluorodeoxyglucose-positron-emission-tomography-in-local-prostate-cancer
#9
Amita Shukla-Dave, Cecilia Wassberg, Darko Pucar, Heiko Schöder, Debra A Goldman, Yousef Mazaheri, Victor E Reuter, James Eastham, Peter T Scardino, Hedvig Hricak
AIM: To assess the relationship using multimodality imaging between intermediary citrate/choline metabolism as seen on proton magnetic resonance spectroscopic imaging ((1)H-MRSI) and glycolysis as observed on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in prostate cancer (PCa) patients. METHODS: The study included 22 patients with local PCa who were referred for endorectal magnetic resonance imaging/(1)H-MRSI (April 2002 to July 2007) and (18)F-FDG-PET/CT and then underwent prostatectomy as primary or salvage treatment...
March 28, 2017: World Journal of Radiology
https://www.readbyqxmd.com/read/28391026/radiopharmaceuticals-in-the-elderly-cancer-patient-practical-considerations-with-a-focus-on-prostate-cancer-therapy-a-position-paper-from-the-international-society-of-geriatric-oncology-task-force
#10
John O Prior, Silke Gillessen, Manfred Wirth, William Dale, Matti Aapro, Wim J G Oyen
Molecular imaging using radiopharmaceuticals has a clear role in visualising the presence and extent of tumour at diagnosis and monitoring response to therapy. Such imaging provides prognostic and predictive information relevant to management, e.g. by quantifying active tumour mass using positron emission tomography/computed tomography (PET/CT). As these techniques require only pharmacologically inactive doses, age and potential frailty are generally not important. However, this may be different for therapy involving radionuclides because the radiation can impact normal bodily function (e...
April 6, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28390533/applications-of-pet-mr-imaging-in-urogynecologic-and-genitourinary-cancers
#11
REVIEW
Jorge D Oldan, Shetal N Shah, Tracy Lynn Rose
Positron emission tomograph (PET)-magnetic resonance (MR) is a new modality combining PET and MR. In gynecologic cancers it can be used for staging of cervical and endometrial cancer, planning of radiation therapy in cervical cancer, assessing response to chemotherapy in ovarian cancer, and detection of recurrence in most gynecologic cancers. It is being explored for prostate cancer and other genitourinary cancers, but is still in experimental stages.
May 2017: Magnetic Resonance Imaging Clinics of North America
https://www.readbyqxmd.com/read/28389027/role-of-pet-ct-with-18-f-fluorocholine-in-biochemical-recurrence-after-treatment-of-prostate-cancer-with-curative-intent
#12
I Puche-Sanz, E Triviño-Ibáñez, F Vázquez-Alonso, J M Llamas-Elvira, J M Cózar-Olmo, A Rodríguez-Fernández
OBJECTIVES: To analyse the ability of the PET-CT with (18)F-fluorocholine ((18)F-FCH) to detect disease on biochemical recurrence after treatment with curative intent. To determine the clinical variables that would be able to optimise the test's diagnostic yield. MATERIAL AND METHODS: A retrospective study of PET-CTs with (18)F-fluorocholine performed on 61 patients with prostate cancer who had undergone treatment with curative intent and met the criteria for biochemical recurrence...
April 4, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28385791/reader-training-for-the-re-staging-of-biochemically-recurrent-prostate-cancer-using-fluciclovine-18-f-pet-ct
#13
Matthew P Miller, Lale Kostakoglu, Daniel Pryma, Jian Qin Yu, Albert Chau, Eric Perlman, Bonnie Clarke, Donald Rosen, Penelope Ward
Fluciclovine ((18)F) is a novel positron emission tomography (PET)/computerised tomography (CT) tracer. This blinded image evaluation (BIE) sought to demonstrate that, after limited training, readers naïve to fluciclovine ((18)F), could interpret fluciclovine ((18)F) images from subjects with biochemical recurrent (BCR) prostate cancer with acceptable diagnostic performance and reproducibility. The primary objectives were to establish individual readers' diagnostic performance and the overall interpretation (2/3 reader concordance) compared to standard of truth (SOT) data (histopathology and/or clinical follow-up) and to evaluate inter-reader reproducibility...
April 6, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28383319/clinical-significance-of-incidental-prostatic-fluorine-18-fluorodeoxyglucose-uptake-in-the-diagnosis-of-infectious-prostatitis-in-adult-males
#14
Gil Ho Lee, Jai Hyuen Lee
BACKGROUND: We performed a work-up study of cancer patients with incidentally found uncharacterized prostatic fluorine-18-fluorodeoxyglucose (F-FDG) uptake in F-FDG PET/CT results. Then, we evaluated the clinical significance of the incidental prostate F-FDG uptake (IPU) in nonmalignant prostate tissues. PATIENTS AND METHODS: Overall, 51 men agreed to a physical prostate examination and an expressed prostatic secretion (EPS) test within 2 weeks after torso F-FDG PET/CT scans...
April 5, 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28379896/spectrum-of-metastatic-and-nonmetastatic-skeletal-findings-with-dual-phase-18f-fech-pet-ct-in-patients-with-biochemical-relapse-of-prostate-cancer
#15
Athar Haroon, Rizwan Syed, Raymond Endozo, Rayjanah Allie, Alex Freeman, Mark Emberton, Jamshed Bomanji
INTRODUCTION: The aim of this study was to evaluate the spectrum of skeletal findings on dual-phase fluorine-18-fluoroethylcholine (F-FECH) PET/CT performed during the work-up of patients referred for suspected prostate cancer relapse. MATERIALS AND METHODS: Three hundred F-FECH PET/CT scans were evaluated prospectively. The low-dose CT features of all cases were categorized as isodense, sclerotic, lytic or mixed lytic/sclerotic and maximum standardized uptake value (SUVmax) values were calculated...
May 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28377141/patterns-of-lymph-node-positivity-on-11-c-acetate-pet-imaging-in-correlation-to-the-rtog-pelvic-radiation-field-for-prostate-cancer
#16
Chris McClinton, Maryam Niroumand, Sumit Sood, Veer Shah, Jacqueline Hill, Reginald W Dusing, Xinglei Shen
PURPOSE: (11)C-acetate positron emission tomography (PET) imaging allows for the detection of occult metastatic disease that may otherwise go undetected with standard imaging for prostate cancer (PCa). The aim of this study was to evaluate lymph node coverage of the standard Radiation Therapy Oncology Group (RTOG) whole pelvic radiation therapy (WPRT) field in patients found to have node-positive PCa determined by (11)C-acetate PET imaging. METHODS AND MATERIALS: A retrospective analysis was conducted on 125 PCa patients who underwent (11)C-acetate PET scans at our institution between 2007 and 2014...
March 6, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28377057/synthesis-and-evaluation-of-18-f-labeled-cj-042794-for-imaging-prostanoid-ep4-receptor-expression-in-cancer-with-positron-emission-tomography
#17
Zhengxing Zhang, Joseph Lau, Hsiou-Ting Kuo, Chengcheng Zhang, Nadine Colpo, François Bénard, Kuo-Shyan Lin
The potent and selective prostanoid EP4 receptor antagonist CJ-042794 was radiolabeled with (18)F, and evaluated for imaging EP4 receptor expression in cancer with positron emission tomography (PET). The fluorination precursor, arylboronic acid pinacol ester 4, was prepared in 4 steps with 42% overall yield. (18)F-CJ-042794 was synthesized via a copper-mediated (18)F-fluorination reaction followed by base hydrolysis, and was obtained in 1.5±1.1% (n=2) decay-corrected radiochemical yield. PET/CT imaging and biodistribution studies in mice showed that (18)F-CJ-042794 was excreted through both renal and hepatobiliary pathways with significant retention in blood...
March 27, 2017: Bioorganic & Medicinal Chemistry Letters
https://www.readbyqxmd.com/read/28375169/an-assessment-of-early-response-to-targeted-therapy-via-molecular-imaging-a-pilot-study-of-3-deoxy-3-18-f-fluorothymidine-positron-emission-tomography-18-f-flt-pet-ct-in-prostate-adenocarcinoma
#18
Kalevi Kairemo, Gregory C Ravizzini, Homer A Macapinlac, Vivek Subbiah
Fluorothymidine is a thymidine analog labeled with fluorine-18 fluorothymidine for positron emission tomography ((18)F-FLT-PET) imaging. Thymidine is a nucleic acid that is used to build DNA. Fluorine-18 fluorothymidine ((18)F-FLT) utilizes the same metabolic pathway as does thymidine but has a very low incidence of being incorporated into the DNA (<1%). (18)F-FLT-PET could have a role in the evaluation of response to targeted therapy. We present here a pilot study where we investigated cellular metabolism and proliferation in patients with prostate cancer before and after targeted therapy...
April 4, 2017: Diagnostics
https://www.readbyqxmd.com/read/28368894/herniated-thoracic-spleen-mimicking-lung-metastasis-on-68ga-labeled-prostate-specific-membrane-antigen-pet-ct-in-a-patient-with-prostate-cancer
#19
Dharmender Malik, Rajender K Basher, Apurva Sood, Sudheer Kumar Devana, Anish Bhattacharya, Bhagwant Rai Mittal
We report a case of clinically asymptomatic patient of prostate cancer who was previously subjected to radical prostatectomy presenting with a rising serum prostate-specific antigen level of 6.6 ng/mL. Whole-body PET/CT with Ga-labeled prostate-specific membrane antigen ligand was performed to assess for disease recurrence, which revealed an intense tracer uptake in a soft tissue mass in left hemithorax mimicking lung metastasis; which later turned out to be splenic tissue.
March 31, 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28368893/early-detection-of-bilateral-testicular-metastases-from-prostatic-adenocarcinoma-using-68ga-psma-ligand-pet-ct
#20
Desiree Weiberg, Herbert Radner, Thorsten Derlin, Walter F Thon
We present the case of a 76-year-old man with biochemical relapse after primary therapy for prostate cancer. Ga prostate-specific membrane antigen (PSMA) ligand PET/CT performed for localization of recurrent disease revealed bilateral metastases to the testes. Histopathologic evaluation after bilateral orchiectomy revealed testicular metastases. Metastases to the testes are rare and usually seen in advanced stages. Ga-PSMA ligand PET/CT is a highly sensitive and specific imaging method for the detection of primary and metastatic prostate cancer and has refined diagnostic approaches...
March 31, 2017: Clinical Nuclear Medicine
keyword
keyword
11205
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"